FDA puts Vertex's hepatitis C drug on partial clinical hold

07/26/2013 | Reuters

A midstage trial of Vertex Pharmaceuticals' investigational hepatitis C drug VX-135 was placed on partial clinical hold by the FDA. The move was made after three patients treated with 400 milligrams of the drug had elevated levels of liver enzymes. "We are committed to continuing to work closely with the FDA to provide the data needed to support evaluation of a 200 mg dose of VX-135 in the U.S.," said Chief Medical Officer Robert Kauffman of Vertex.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN